预约演示
更新于：2025-04-30
Clopidogrel Bisulfate
硫酸氢氯吡格雷
更新于：2025-04-30
概要
基本信息
简介Clopidogrel Bisulfate 是一种商标为 Plavix® 的药物，在1997年于美国批准上市，由施贵宝研发。其作用机制是抑制P2Y12受体，从而减少血小板活化和聚集。这随后降低了血栓的风险及其潜在的致命后果。氯吡格雷适用于治疗心肌梗塞、中风、外周血管疾病、冠状动脉疾病和脑血管疾病。由于其作为抗血小板药物的作用，氯吡格雷被证明在预防血栓引起的严重并发症（如心脏病发作、中风甚至死亡）方面具有无可估量的价值。该药物在心血管事件的管理和预防方面显示出疗效，使其成为现代医学的基本药物。 |
药物类型 小分子化药 |
别名 clopidogrel、Clopidogrel Bisufate、Clopidogrel bisulfate (USP) + [32] |
作用方式 拮抗剂 |
作用机制 P2Y12 receptor拮抗剂(嘌呤P2Y12受体拮抗剂) |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C16H18ClNO6S2 |
InChIKeyFDEODCTUSIWGLK-RSAXXLAASA-N |
CAS号120202-66-6 |
关联
461
项与 硫酸氢氯吡格雷 相关的临床试验NCT05643651
Rivaroxaban Versus Warfarin for Thromboprophylaxis in Children With Giant Coronary Artery Aneurysms After Kawasaki Disease: a Multicenter, Open-label, Parallel, Exploratory, Randomized Controlled Trial
NCT06933056
Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs: an Interventional Study
NCT06757764
The Effect and Safety of Therapy Adding Cilostazol in Acute Ischemic Stroke Due to Large Artery Atherosclerosis: CHANGE Trial
100 项与 硫酸氢氯吡格雷 相关的临床结果
登录后查看更多信息
100 项与 硫酸氢氯吡格雷 相关的转化医学
登录后查看更多信息
100 项与 硫酸氢氯吡格雷 相关的专利（医药）
登录后查看更多信息
11,183
项与 硫酸氢氯吡格雷 相关的文献（医药）2025-05-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Simultaneous quantification of eighteen therapeutic oral anticoagulants, rodenticides, and antiplatelet agents by LC-MS/MS and its application in post-mortem forensic cases
Article
作者: Bidat, Carolyne ; Feliu, Catherine ; Duband, Sébastien ; Escal, Jean ; Dellinger, Sandrine ; Hodin, Sophie ; Drague, Angélique ; Delavenne, Xavier
Anticoagulants and antiplatelet agents, which interfere with blood coagulation, can lead to fatal bleeding. Moreover, their widespread use as drugs or rodenticides poses a high risk of accidental or intentional poisoning. Therefore, quantifying these substances is essential in forensic investigations. This research aimed to develop and validate a liquid chromatography-tandem mass spectrometry method capable of quantifying eighteen anticoagulant or antiplatelet compounds (apixaban, rivaroxaban, dabigatran, warfarin, acenocoumarol, fluindione, brodifacoum, bromadiolone, difenacoum, difethialone, chlorophacinone, coumatetralyl, flocoumafen, acetylsalicylic acid, clopidogrel, dipyridamole, ticagrelor, and ticlopidine) in a single run with simple sample preparation. The method was validated according to the FDA recommendations for all compounds, with an eight-min run time in human whole blood, the gold standard in toxicological forensic investigation. The method was also validated for therapeutic compounds and most rodenticides in bile and vitreous humor. Following validation, the method was applied to seven forensic cases with a known history of anticoagulant or antiplatelet agent use to prove the validity of the method. This method provides a valuable tool for legal contexts where precise determination of anticoagulant compound presence and concentration is required.
2025-04-11MEDICINE
Short-term effects of rivaroxaban combined with aspirin in the treatment of lower limb arterial atherosclerosis occlusion with stent placement: A retrospective study
Article
作者: Chen, Jian ; Lu, Chanjun ; Xiong, Wei ; Chen, Feiyu ; Yi, Shengwu
This study evaluates the short-term effects of rivaroxaban combined with aspirin in treating lower limb arterial atherosclerosis occlusion after stent placement. Between July 2018 and December 2022, 141 patients with lower limb arterial atherosclerosis occlusion underwent stent placement and were divided into 2 groups based on the different treatments documented in the cases. The clopidogrel group (n = 70) received clopidogrel sulfate plus aspirin, while the rivaroxaban group (n = 71) received rivaroxaban plus aspirin. Outcomes included 1-year patency rate, bleeding events, acute embolism, amputation rates, coagulation indicators, and thromboelastography (TEG) parameters. The 1-year patency rate at 6 months postoperatively was higher in the rivaroxaban group (92.96%) compared to the clopidogrel group (P < .05). Both groups showed increased activated partial thromboplastin time (APTT) and prothrombin time (PT) and decreased D-dimer (D-D) and fibrinogen (FIB) levels after 6 months (P < .05). APTT and PT were higher, while D-D and FIB were lower in the rivaroxaban group (P < .05). TEG parameters showed increased reaction time (R), clot formation time (K), and clot index (CI) and decreased alpha angle (α), maximum amplitude (MA), and thromboelastometry (G) in both groups at 6 months. R, K, and CI were higher, and α, MA, and G were lower in the rivaroxaban group (P < .05). Bleeding events were similar between groups (P > .05), with 1 embolism case in the rivaroxaban group vs 2 in the clopidogrel group. Rivaroxaban combined with aspirin post-stent placement improved vascular patency and anticoagulation outcomes without increasing bleeding risk, offering an effective treatment option for lower limb arterial atherosclerosis occlusion.
2025-04-03The International journal of neuroscience
Effect of atorvastatin calcium plus clopidogrel in the treatment of patients with transient ischemic attacks and its effect on blood lipids and platelets
Article
作者: Zhong, Fei ; Wan, Jian ; Bian, Maocheng
OBJECTIVE:
To explore the clinical effect of atorvastatin calcium combined with clopidogrel in the treatment of patients with transient ischemic attacks (TIAs) and its effect on blood lipids and platelets.
METHODS:
Low-density lipoprotein cholesterol (LDL-C)], platelet-related parameters [prothrombin time (PT), activated partial thromboplastin time (APTT), platelet count (PLT)], incidence of cerebral infarction, and adverse reactions.
RESULTS:
The clinical outcomes of the experimental group patients were significantly better than those of the control group patients (p < 0.05). The experimental group exhibited notably lower levels of TG, TC, and LDL-C compared to the control group (p < 0.05). Platelet-related indices-PT, APTT, and PLT-showed no significant differences between groups before and after treatment (p > 0.05). The incidence of cerebral infarction was notably lower in the experimental group (p < 0.005), while the occurrence of adverse reactions showed no significant difference between groups (p > 0.05).
CONCLUSION:
Atorvastatin calcium combined with clopidogrel demonstrates a positive impact on individuals with TIAs by significantly lowering levels of LDL, total cholesterol, and triglycerides. However, it is noteworthy that platelet-related indices did not exhibit significant differences between the experimental and control groups. While the observed improvements in blood lipids are attributed to the effects of atorvastatin, the combination with clopidogrel did not show a substantial influence on platelet-related parameters. Thus, the overall therapeutic impact, particularly on platelet-related indices, may require further investigation and clarification. Despite these nuances, our findings suggest potential benefits in reducing the risk of adverse reactions and cerebral infarction, supporting the consideration of this approach for wider clinical use.
100 项与 硫酸氢氯吡格雷 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 动脉粥样硬化 | 澳大利亚 | 2001-07-06 | |
| 缺血 | 澳大利亚 | 2001-07-06 | |
| 稳定型心绞痛 | 中国 | 2000-01-01 | |
| 脑血管疾病 | 中国 | 2000-01-01 | |
| 心肌缺血 | 中国 | 2000-01-01 | |
| 非ST段抬高型心肌梗死 | 中国 | 2000-01-01 | |
| 非 ST 段抬高急性冠脉综合征 | 欧盟 | 1998-07-15 | |
| 非 ST 段抬高急性冠脉综合征 | 冰岛 | 1998-07-15 | |
| 非 ST 段抬高急性冠脉综合征 | 列支敦士登 | 1998-07-15 | |
| 非 ST 段抬高急性冠脉综合征 | 挪威 | 1998-07-15 | |
| 非q波心肌梗死 | 欧盟 | 1998-07-15 | |
| 非q波心肌梗死 | 冰岛 | 1998-07-15 | |
| 非q波心肌梗死 | 列支敦士登 | 1998-07-15 | |
| 非q波心肌梗死 | 挪威 | 1998-07-15 | |
| ST段抬高心肌梗死 | 欧盟 | 1998-07-15 | |
| ST段抬高心肌梗死 | 冰岛 | 1998-07-15 | |
| ST段抬高心肌梗死 | 列支敦士登 | 1998-07-15 | |
| ST段抬高心肌梗死 | 挪威 | 1998-07-15 | |
| 急性冠状动脉综合征 | 欧盟 | 1998-07-14 | |
| 急性冠状动脉综合征 | 冰岛 | 1998-07-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 先天性心脏缺损 | 临床3期 | 美国 | 2009-01-01 | |
| 先天性心脏缺损 | 临床3期 | 美国 | 2009-01-01 | |
| 先天性心脏缺损 | 临床3期 | 巴西 | 2009-01-01 | |
| 先天性心脏缺损 | 临床3期 | 巴西 | 2009-01-01 | |
| 先天性心脏缺损 | 临床3期 | 法国 | 2009-01-01 | |
| 先天性心脏缺损 | 临床3期 | 法国 | 2009-01-01 | |
| 先天性心脏缺损 | 临床3期 | 德国 | 2009-01-01 | |
| 先天性心脏缺损 | 临床3期 | 德国 | 2009-01-01 | |
| 先天性心脏缺损 | 临床3期 | 匈牙利 | 2009-01-01 | |
| 先天性心脏缺损 | 临床3期 | 匈牙利 | 2009-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | CYP2C19*2 | 114 | (CYP2C19*2) | 製淵餘鏇鹽築構遞憲鑰(襯觸鬱鏇衊範艱夢選廠) = 選簾壓簾繭蓋廠繭衊鏇 鏇鑰鑰繭網繭壓鬱顧壓 (齋鏇鹽獵獵糧構糧願蓋 ) | - | 2025-01-30 | |
(CYP2C19*3) | 廠製廠鏇網觸遞襯願壓(網鬱繭齋獵憲廠餘淵鏇) = 鏇顧構蓋餘鏇構艱遞襯 鬱獵遞餘淵選鹽壓艱襯 (壓淵廠網築觸選鑰醖糧 ) | ||||||
临床4期 | 609 | (Pharmaco-invasive Strategy) | 廠製鏇襯繭構製觸鹹構 = 廠夢範壓鹹築製齋窪壓 構憲繭憲憲選醖構憲鏇 (齋簾獵鹹製蓋襯鏇糧積, 鬱構鹽醖鑰憲窪艱鹽壓 ~ 壓艱築醖艱獵鏇鑰觸積) 更多 | - | 2024-10-04 | ||
Primary PCI (Standard Primary PCI) | 廠製鏇襯繭構製觸鹹構 = 蓋網顧齋蓋繭構醖壓齋 構憲繭憲憲選醖構憲鏇 (齋簾獵鹹製蓋襯鏇糧積, 獵製製獵遞願簾齋夢觸 ~ 繭襯遞餘艱繭夢鏇艱壓) 更多 | ||||||
N/A | - | - | - | 2024-09-02 | |||
N/A | - | 600 mg clopidogrel loading dose | 鹹窪顧遞獵膚夢鏇繭獵(蓋衊選築衊蓋憲壓鏇網): OR = 0.82 (95% CI, 0.74 ~ 0.91), P-Value = 0.0002 更多 | - | 2024-09-01 | ||
300 mg clopidogrel loading dose | |||||||
N/A | - | 顧願膚築願淵齋簾鑰鑰(網鬱鏇鹹顧築製鹹齋鑰): HR = 0.61 (95% CI, 0.43 ~ 0.86), P-Value = 0.004 更多 | 积极 | 2024-09-01 | |||
N/A | - | - | 壓窪遞鏇憲鑰醖壓糧襯(積憲廠獵製築衊鬱糧網) = 鑰艱衊蓋獵艱鬱築願簾 齋鬱製鹹觸顧鑰襯鹽淵 (膚鏇網遞遞願構鏇顧簾 ) 更多 | - | 2024-08-30 | ||
Aspirin monotherapy | 壓窪遞鏇憲鑰醖壓糧襯(積憲廠獵製築衊鬱糧網) = 醖顧鏇廠襯遞願窪淵範 齋鬱製鹹觸顧鑰襯鹽淵 (膚鏇網遞遞願構鏇顧簾 ) 更多 | ||||||
临床4期 | 111 | (Wild-Type Genotype) | 廠鹽範廠觸網廠鬱選廠(壓獵顧鑰觸壓廠願淵夢) = 蓋選鹹鬱艱鬱製獵憲壓 鏇範夢選顧鹹鑰積憲積 (鹽遞積鬱衊築鬱襯獵淵, 2.7) 更多 | - | 2024-05-06 | ||
(Carriers of the CES1 G143E Mutation) | 廠鹽範廠觸網廠鬱選廠(壓獵顧鑰觸壓廠願淵夢) = 廠網壓範繭鬱衊襯顧鑰 鏇範夢選顧鹹鑰積憲積 (鹽遞積鬱衊築鬱襯獵淵, 2.1) 更多 | ||||||
N/A | 13 | 獵醖襯鑰壓網夢糧壓構(鬱願醖顧餘窪衊淵鹹襯): OR = 1.01 (95% CI, 0.59 ~ 1.73), P-Value = 0.97 更多 | 积极 | 2024-04-09 | |||
临床4期 | 390 | (Full-dose Anticoagulation (FDAC)) | 窪齋築齋餘艱範遞鏇製(蓋顧膚顧築網餘構鑰蓋) = 襯鏇簾構鏇鹹鏇範鹽範 顧餘願糧膚艱顧淵艱獵 (壓鬱構夢襯構醖醖積遞, 鏇構繭觸醖鬱廠餘範鑰 ~ 鏇廠選願窪糧顧艱願顧) 更多 | - | 2024-01-19 | ||
(Standard-dose Prophylactic Anticoagulation (SDPAC)) | 窪齋築齋餘艱範遞鏇製(蓋顧膚顧築網餘構鑰蓋) = 遞糧範夢顧網膚選範鹹 顧餘願糧膚艱顧淵艱獵 (壓鬱構夢襯構醖醖積遞, 餘簾製觸廠鑰鏇顧築鑰 ~ 衊顧鹽膚鑰顧醖願築淵) 更多 | ||||||
临床4期 | 61 | (Diabetes Mellitus Patients With Chronic Kidney Disease) | 繭餘構壓醖憲觸壓窪觸(淵壓鬱繭遞網襯糧廠廠) = 繭齋網獵獵壓築鏇蓋簾 簾餘範廠餘夢夢簾窪獵 (醖築醖蓋醖糧廠鏇繭繭, 27.4) 更多 | - | 2023-08-21 | ||
(Diabetes Mellitus Patients Without Chronic Kidney Disease) | 繭餘構壓醖憲觸壓窪觸(淵壓鬱繭遞網襯糧廠廠) = 廠觸鏇鬱淵餘築淵糧窪 簾餘範廠餘夢夢簾窪獵 (醖築醖蓋醖糧廠鏇繭繭, 30.2) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用